5Furuhata K,Hiraiwa T,Ono S,et al. General pharmacology of T-3761,a new oral quinolone antibacterial agent(1).Effect on the central nervous agent[J].Jpn J Antibiot,1995,48(5):692-705.
6Fukuda H,Kawamura Y. Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate,a new quinolone antibacterial agent for intravenous use:convulsions in mice after intravenous or intracerebroventricular administration[J].Jpn J Antibiot,2002,55(3):270-280.
7Furuhata K,Hayakawa H,Soumi K,et al. Histamine-releasing properties of T-3761,a novel fluoroquinolone antimicrobial agent in intravenous use.I.Effect of dose and infusion rate on blood pressure,heart rate and plasma histamine concentration[J].Biol Pharm Bull,1998,21(5):456-460.
8Furuhata K,Fukuda Y,Soumi K,et al. Histamine-releasing properties of T-3762,a novel fluoroquinolone antimicrobial agent in intravenous use II. Dermovascular permeability increasing effect and action on peritoneal mast cells[J].Biol Pharm Bull,1998,21(5):461-464.
9Nakagawa S,Iwai N,Komae N,et al. Single administration toxicity studies of T-3761 in mice,rats and dogs[J].Jpn J Antibiot,1995,48(6):754-768.
10Kawamura Y,Nagai A,Yoshida K,et al. Three months oral repeated dose toxicity of T-3761 in rats[J].Jpn J Antibiot,1995,48(6):769-789.
二级参考文献1
1Nakashima M Uemura K Kosuge K et al.Phase Ⅰ clinical study of pazufloxacin mesilate [J].Japan J Chemother,1999,47(1):141-141.
9Kobayashi H. Interim results from a multi-centre clinical trial of T-3761 in Japan[J]. Drug, 1995, 49 (Suppl 2) : 470-471.
10Domagala JM. Structure-activity and structure-side effect relationships for the quinolone antibacterials[ J]. J Antimicrob Chemother, 1994, 33(4) :685.
